by Plus Therapeutics | Nov 3, 2025 | Uncategorized
Plus Therapeutics (NASDAQ: PSTV) was recently highlighted in an article by Mary Caffrey in The American Journal of Managed Care (AJMC) — one of the leading peer-reviewed journals covering the intersection of clinical innovation, policy, and patient access. The...
by Plus Therapeutics | Oct 27, 2025 | Uncategorized
Last weekend, members of the Plus Therapeutics team — led by Gabby Cleveland — participated in the 7th Annual Head for the Cure Foundation 5K in Phoenix, Arizona, standing alongside patients, caregivers, and advocates united in the fight against brain cancer. This...
by Plus Therapeutics | Oct 23, 2025 | Uncategorized
Plus Therapeutics’ President & CEO, Marc Hedrick, M.D., was recently featured as a key opinion leader in a Nature Cancer article by Melanie Senior highlighting how biotechnology companies are advancing the next generation of radiopharmaceutical therapies ahead of...
by Plus Therapeutics | Oct 15, 2025 | PBC
Designing clinical trials for children isn’t as simple as shrinking adult trials — and that’s exactly why awareness and advocacy matter. Pediatric cancers are rare, meaning fewer patients to enroll, longer trial timelines, and unique ethical and medical challenges...
by Plus Therapeutics | Oct 14, 2025 | LM
Last week, CNSide® Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining Houston’s growing network of researchers, entrepreneurs, and clinicians driving the future of biotech innovation. The discussion centered...
Recent Comments